Celcuity (CELC) Research & Development (2016 - 2026)
Celcuity's (CELC) quarterly Research & Development came in at $37.6 million in Q4 2025, up 12.44% YoY from $33.5 million in Q4 2024, and up 7.79% on a QoQ basis from $34.9 million in Q3 2025.
Analysis
Celcuity (CELC) Research & Development (2016 - 2026) Analysis & Trends
Celcuity (CELC) has 10 years of Research & Development data on file, last reported at $37.6 million in Q4 2025.
- Quarterly Research & Development rose 12.44% year-over-year to $37.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $145.0 million (up 39.15% YoY) and the FY2025 annual result came in at $145.0 million, up 39.15% from the prior year.
- Research & Development improved to $37.6 million in Q4 2025, from $34.9 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $40.2 million in Q2 2025 to a low of $2.2 million in Q1 2021.
- A 5-year average of $18.5 million and a median of $15.6 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2021 — Research & Development jumped 640.0% — and 2022, when it tumbled 35.98%.
- Tracing CELC's Research & Development over 5 years: stood at $5.5 million in 2021, then surged by 93.12% to $10.6 million in 2022, then soared by 70.51% to $18.1 million in 2023, then soared by 85.11% to $33.5 million in 2024, then increased by 12.44% to $37.6 million in 2025.
- The last three Research & Development figures came in at $37.6 million (Q4 2025), $34.9 million (Q3 2025), and $40.2 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn | -486.00 Mn |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | 651.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 394.92 Mn |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn | 612.28 Mn |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn | 413.13 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - | 97.90 Mn |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Celcuity | 5.27 Bn | 5.27 Bn | - | 31.08 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 31.08 Mn |
| Dec 31, 2025 | 37.64 Mn |
| Sep 30, 2025 | 34.92 Mn |
| Jun 30, 2025 | 36.42 Mn |
| Mar 31, 2025 | 32.23 Mn |
| Dec 31, 2024 | 33.47 Mn |
| Sep 30, 2024 | 27.59 Mn |
| Jun 30, 2024 | 22.50 Mn |
| Mar 31, 2024 | 20.65 Mn |
| Dec 31, 2023 | 18.08 Mn |
| Sep 30, 2023 | 17.49 Mn |
| Jun 30, 2023 | 13.75 Mn |
| Mar 31, 2023 | 11.28 Mn |
| Dec 31, 2022 | 10.60 Mn |
| Sep 30, 2022 | 9.62 Mn |
| Jun 30, 2022 | 8.37 Mn |
| Mar 31, 2022 | 6.70 Mn |
| Dec 31, 2021 | 5.49 Mn |
| Sep 30, 2021 | 4.96 Mn |
| Jun 30, 2021 | 13.07 Mn |